Lee Jennifer Kayden 4

4 · RHYTHM PHARMACEUTICALS, INC. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

RHYTHM (RYTM) EVP Jennifer Kayden Receives 22,612 Shares

What Happened

Jennifer Kayden, EVP & Head of North America at Rhythm Pharmaceuticals (RYTM), had restricted stock units (RSUs) convert into 22,612 shares on February 1, 2026. Of those, 9,237 shares were withheld to cover tax withholding at $108.99 per share, producing $1,006,741. After withholding, Kayden received a net ~13,375 shares.
This was RSU vesting/conversion (reported under derivative code M) with tax withholding (code F). This is an award/vesting event, not an open-market sale or a purchase.

Key Details

Transaction date: February 1, 2026; Filing date: February 3, 2026 (timely filing within the usual 2-business-day window).
Withheld shares: 9,237 @ $108.99 = $1,006,741 (tax withholding). Total RSUs converted: 22,612.
Other line items (3,437; 4,512; 5,500; 9,163) reflect the component conversions of the total 22,612 shares (reported with $0 value in the filing); footnote F2 confirms shares were withheld to pay withholding taxes.
Footnotes F1–F6: these are RSU grants with staggered vesting schedules (25% cliffs on the dates listed) and no expiration date.
Shares owned after the transaction: not specified in the filing.

Context

This was a routine vesting/settlement of RSUs with shares withheld to satisfy tax liabilities (a common cashless settlement). It is not an open-market sale by the insider; the withholding is effectively a company-arranged disposition to cover taxes.
For retail investors: award vesting increases insider's ownership (net ~13,375 shares added here) but is compensation-related rather than a direct market purchase that signals personal conviction.

Form 4

Period: 2026-02-01

EVP, Head of North America

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-01+22,612→ 28,470 total
Tax Payment
Common Stock
[F2]
2026-02-01$108.99/sh−9,237$1,006,741→ 19,233 total
Exercise/Conversion
Restricted Stock Units
[F1][F3]
2026-02-01−3,437→ 0 total
→ Common Stock (3,437 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-02-01−4,512→ 4,512 total
→ Common Stock (4,512 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F5]
2026-02-01−5,500→ 11,000 total
→ Common Stock (5,500 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F6]
2026-02-01−9,163→ 27,487 total
→ Common Stock (9,163 underlying)

Footnotes (6)

[F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
[F2]These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein.
[F3]The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 1, 2026. The restricted stock units have no expiration date.
[F4]The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.
[F5]The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date.
[F6]The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date.

Signature

/s/ Stephen Vander Stoep, Attorney-in-Fact for Jennifer Kayden Lee|2026-02-03

1 file